Figure 4.

Targeting CD146 synergized with vorinostat to substantially inhibit ovarian cancer growth. (A) When the tumor reached a diameter of 5–6 mm, SKOV3 tumor-bearing mice were grouped (n=10) and administered intraperitoneally with PBS (black), 8 mg/kg mAb AA98 (green), 20 mg/kg vorinostat plus mIgG (brown), or vorinostat plus mAb AA98 (blue). Mean tumor volumes were monitored at specific time points subsequent to treatment. Each data point represents mean ± standard deviation (*P<0.05; n=10). (B) Kaplan-Meier survival curves of SKOV3 tumor-bearing mice following various treatments as indicated. Each group consisted of 10 animals. PBS served as a control. CD146, cluster of differentiation 146; mAb, monoclonal antibody; mIgG, monoclonal immunoglobulin G; SAHA, suberoylanilide hydroxamic acid.